These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 26644411)

  • 21. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
    Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
    Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
    Kim A; Dombi E; Tepas K; Fox E; Martin S; Wolters P; Balis FM; Jayaprakash N; Turkbey B; Muradyan N; Choyke PL; Reddy A; Korf B; Widemann BC
    Pediatr Blood Cancer; 2013 Mar; 60(3):396-401. PubMed ID: 22961690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological evaluation of a novel sorafenib analogue, t-CUPM.
    Wecksler AT; Hwang SH; Liu JY; Wettersten HI; Morisseau C; Wu J; Weiss RH; Hammock BD
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):161-71. PubMed ID: 25413440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
    Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
    Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
    Huillard O; Boissier E; Blanchet B; Thomas-Schoemann A; Cessot A; Boudou-Rouquette P; Durand JP; Coriat R; Giroux J; Alexandre J; Vidal M; Goldwasser F
    Expert Opin Drug Saf; 2014 May; 13(5):663-73. PubMed ID: 24693873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
    Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
    Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
    [No Abstract]   [Full Text] [Related]  

  • 27. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
    Kumar SK; Jett J; Marks R; Richardson R; Quevedo F; Moynihan T; Croghan G; Markovic SN; Bible KC; Qin R; Tan A; Molina J; Kaufmann SH; Erlichman C; Adjei AA
    Invest New Drugs; 2013 Oct; 31(5):1201-6. PubMed ID: 23887852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of pemetrexed with sorafenib in advanced solid tumors.
    Poklepovic A; Gordon S; Shafer DA; Roberts JD; Bose P; Geyer CE; McGuire WP; Tombes MB; Shrader E; Strickler K; Quigley M; Wan W; Kmieciak M; Massey HD; Booth L; Moran RG; Dent P
    Oncotarget; 2016 Jul; 7(27):42625-42638. PubMed ID: 27213589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
    Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
    Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
    Edelman G; Rodon J; Lager J; Castell C; Jiang J; Van Allen EM; Wagle N; Lindeman NI; Sholl LM; Shapiro GI
    Oncologist; 2018 Apr; 23(4):401-e38. PubMed ID: 29593099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
    Worden F; Fassnacht M; Shi Y; Hadjieva T; Bonichon F; Gao M; Fugazzola L; Ando Y; Hasegawa Y; Park DJ; Shong YK; Smit JW; Chung J; Kappeler C; Meinhardt G; Schlumberger M; Brose MS
    Endocr Relat Cancer; 2015 Dec; 22(6):877-87. PubMed ID: 26370187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
    Shapiro GI; Rodon J; Bedell C; Kwak EL; Baselga J; Braña I; Pandya SS; Scheffold C; Laird AD; Nguyen LT; Xu Y; Egile C; Edelman G
    Clin Cancer Res; 2014 Jan; 20(1):233-45. PubMed ID: 24166903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sorafenib in patients with refractory or recurrent multiple myeloma.
    Yordanova A; Hose D; Neben K; Witzens-Harig M; Gütgemann I; Raab MS; Moehler T; Goldschmidt H; Schmidt-Wolf IG
    Hematol Oncol; 2013 Dec; 31(4):197-200. PubMed ID: 23494836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.
    Nakamichi S; Nokihara H; Yamamoto N; Yamada Y; Fujiwara Y; Tamura Y; Wakui H; Honda K; Mizugaki H; Kitazono S; Tanabe Y; Asahina H; Yamazaki N; Suzuki S; Matsuoka M; Ogita Y; Tamura T
    Invest New Drugs; 2015 Jun; 33(3):641-51. PubMed ID: 25809858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Saturable absorption of sorafenib in patients with solid tumors: a population model.
    Hornecker M; Blanchet B; Billemont B; Sassi H; Ropert S; Taieb F; Mir O; Abbas H; Harcouet L; Coriat R; Dauphin A; Goldwasser F; Tod M
    Invest New Drugs; 2012 Oct; 30(5):1991-2000. PubMed ID: 22006162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study.
    Fucile C; Marenco S; Bazzica M; Zuccoli ML; Lantieri F; Robbiano L; Marini V; Di Gion P; Pieri G; Stura P; Martelli A; Savarino V; Mattioli F; Picciotto A
    Med Oncol; 2015 Jan; 32(1):335. PubMed ID: 25429830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer.
    Bellesoeur A; Carton E; Mir O; Groussin L; Blanchet B; Billemont B; Clerc J; Goldwasser F
    Invest New Drugs; 2014 Jun; 32(3):569-72. PubMed ID: 24399106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.
    Mai H; Huang J; Zhang Y; Qu N; Qu H; Mei GH; Liu J; Xu X; Chen L
    Oncotarget; 2017 Jun; 8(26):43458-43469. PubMed ID: 28404979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychotic disorder induced by a combination of sorafenib and BAY86-9766.
    Kuo YL; Yang YK; Cheng HC; Yen CJ; Chen PS
    Gen Hosp Psychiatry; 2014; 36(4):450.e5-7. PubMed ID: 24773940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.